Summer, I think the results for IPI-504 may be the worst clinical trial results I've ever seen, certainly for a drug that got as far as phase 2. Virtually no improvement in PSA or tumor burden, the chosen endpoints, and "unacceptable levels of toxicity" including a couple of deaths (in a small population) that appeared to be drug-related.
Fortunately, OGX-427 is targeting a different heat shock protein in a different way, and if the phase 1 results mean anything the phase 2 results will at least be better than those for Infinity's drug.
I share the hope you expressed in a different post that OGXI will finally provide some timeline guidance on its trials tomorrow. OGXI has had quite a news drought of late. I don't think we've heard from Cormack since the Q1 conference call. I can barely remember what he sounds like.
A minor observation: I notice that they no longer seem to be listing SN-2310 as a product candidate. I guess they've given up on trying to outlicense it.